Substituted Indane Solid Dispersions for HIF-2α Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for conditions associated with hypoxia-inducible factor-2α (HIF-2α) dysregulation, such as von Hippel-Lindau disease and renal cell carcinoma, lack effective methods to target and inhibit HIF-2α activity, leading to poor patient prognosis and inadequate oxygen supply to tissues.
Innovation Solution
A solid dispersion comprising a compound of Formula (I) and a pharmaceutically acceptable polymer, such as HPMCAS, is developed, which can be formulated into tablets or capsules for oral delivery, providing a stable and bioavailable form that inhibits HIF-2α activity and improves tissue oxygenation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If HIF-2α is dysregulated in cancers, then tumor growth and angiogenesis are promoted, but patient prognosis deteriorates
Solution Approach 1:
The patent extracts and isolates the harmful HIF-2α activity from the cellular system by using specific compounds (Formula I) that selectively inhibit HIF-2α function. This separation allows normal cellular processes to proceed while preventing the harmful effects of HIF-2α-driven angiogenesis and tumor growth.
Solution Approach 2:
The patent changes the functional state of HIF-2α from active to inhibited by introducing specific molecular compounds. These compounds alter the biochemical parameters of HIF-2α activity, reducing its ability to bind DNA and regulate target genes, thereby improving patient prognosis while maintaining normal physiological functions.
2Reliability
If solid dispersion is formulated with polymer, then bioavailability is improved, but manufacturing complexity increases
Solution Approach 1:
The patent introduces a polymer as an intermediary carrier that facilitates the delivery of the active compound. The polymer forms a solid dispersion matrix that improves solubility and bioavailability of the compound, while the patent simplifies the manufacturing process by providing specific polymer selections and formulation ratios.
Solution Approach 2:
The patent optimizes formulation parameters including polymer type, compound-to-polymer ratio, and processing conditions to achieve optimal bioavailability. By systematically varying these parameters and identifying optimal ranges, the patent improves drug delivery while controlling manufacturing complexity through standardized formulation protocols.
Data Source
AI summary
Provided herein are solid dispersions comprising a HIF-2a inhibitor, pharmaceutical compositions comprising the solid dispersions, and methods for treating HIF-2a-mediated diseases and conditions.